The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

Entity Type

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

0001371217 EnteroMedics Inc X Corporation

Name of Issuer Limited Partnership

ReShape Lifesciences Inc.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral Partnership
Business TrustDELAWAREOther (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

ReShape Lifesciences Inc.

Street Address 1 Street Address 2

1001 CALLE AMANECER

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

SAN CLEMENTE CALIFORNIA 92673 9494296680

3. Related Persons

Last Name First Name Middle Name

Gladney Dan

Street Address 1 Street Address 2

1001 CALLE AMANECER

City State/Province/Country ZIP/PostalCode

San Clemente CALIFORNIA 92673

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Youngstrom Scott

Street Address 1 Street Address 2

1001 CALLE AMANECER

City State/Province/Country ZIP/PostalCode

San Clemente CALIFORNIA 92673

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Blackford Gary

> **Street Address 1 Street Address 2**

1001 CALLE AMANECER

State/Province/Country ZIP/PostalCode City

San Clemente **CALIFORNIA** 92673

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Tremmel Jon

> **Street Address 1 Street Address 2**

1001 CALLE AMANECER

City State/Province/Country ZIP/PostalCode

San Clemente **CALIFORNIA** 92673

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Lori McDougal

> **Street Address 2 Street Address 1**

1001 CALLE AMANECER

City State/Province/Country ZIP/PostalCode

CALIFORNIA San Clemente 92673

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing Banking & Financial Services

Biotechnology Restaurants Commercial Banking Health Insurance Technology Insurance

Hospitals & Physicians Computers Investing

Pharmaceuticals Telecommunications **Investment Banking**

Pooled Investment Fund X Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under Real Estate Airlines & Airports the Investment Company

Commercial Act of 1940? **Lodging & Conventions** Construction Yes No Tourism & Travel Services

Other

REITS & Finance Other Banking & Financial Services Other Travel

Business Services Residential

Other Real Estate Coal Mining

Environmental Services Oil & Gas

Energy Conservation

Other Energy

Electric Utilities

Energy

Recipient

H.C. Wainwright & Co., LLC

J. 133uei 31ze						
Revenue Range	OR	Aggregate Net Asset Value Range				
No Revenues		No Aggregate Ne	et Asset Value			
\$1 - \$1,000,000		\$1 - \$5,000,000				
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000				
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000				
\$25,000,001 - \$100,000,000		\$50,000,001 - \$1	00,000,000			
Over \$100,000,000		Over \$100,000,0	00			
X Decline to Disclose		Decline to Disclose				
Not Applicable		Not Applicable				
6. Federal Exemption(s) and Exclu	ısion(s) Claim	ned (select all that a	apply)			
Investment Company Act Section 3(c)						
Rule 504(b)(1) (not (i), (ii) or (iii))		Section 3(c)((1) Section 3(c)(9)			
Rule 504 (b)(1)(i)		Section 3(c)	(2) Section 3(c)(10)			
Rule 504 (b)(1)(ii)		Section 3(c)(
Rule 504 (b)(1)(iii)						
X Rule 506(b)		Section 3(c)				
Rule 506(c)		Section 3(c)	(5) Section 3(c)(13)			
Securities Act Section 4(a)(5)		Section 3(c)	(6) Section 3(c)(14)			
		Section 3(c)(7)			
7. Type of Filing						
X New Notice Date of First Sale Amendment	2018-06-07	First Sale Yet to	Occur			
8. Duration of Offering						
Does the Issuer intend this offerin	g to last more	than one year?	Yes X No			
9. Type(s) of Securities Offered (se	elect all that a	pply)				
Equity Pooled Investment Fund Interests						
Debt			Tenant-in-Common Securities			
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities						
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other Right to Acquire Security						
10. Business Combination Transac	ction					
Is this offering being made in containing a merger, acquisition or exchange		a business combina	tion transaction, such as Yes X No			
Clarification of Response (if Nece	ssary):					
11. Minimum Investment						
Minimum investment accepted from	om any outside	e investor \$0 USD				
12. Sales Compensation						

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

Recipient CRD Number None

375

None None

Street Address 1 Street Address 2

430 Park Avenue

City State/Province/Country ZIP/Postal Code

New York NEW YORK 10022

State(s) of Solicitation (select all that apply) Check "All States" or check individual States

All States Foreign/non-US

CALIFORNIA
FLORIDA
NEW JERSEY
NEW YORK

13. Offering and Sales Amounts

Total Offering Amount \$1,235,413 USD or Indefinite

Total Amount Sold \$1,235,413 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

The warrants and underlying shares of common stock include warrants (i) to purchase 280,929 shares of common stock issued to certain institutional investors and (ii) to purchase 26,220 shares of common stock to H.C. Wainwright ("HCW Warrants").

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

4

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$2,809 USD Estimate
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

H.C. Wainwright received the above sales commission in connection with the private placement of warrants. The HCW Warrants were issued to H.C. Wainwright in connection with a registered direct offering by the Company, which is not reported on this Form D

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
ReShape Lifesciences Inc.	/s/ Scott Youngstrom	Scott Youngstrom	CFO and Chief Compliance Officer	2018-06-22

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.